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Abstract
In this second article we describe the more interesting pharmacological interactions in dental practice based 
on the prescription of analgesic narcotics, paracetamol and non-selective non-steroid anti-inflammatory drugs 
(NSAI) (which inhibit cyclooxigenase 1 –COX 1- and cyclooxigenase 2 –COX 2-)  and  selective NSAIs (COX 2 
inhibitors). The importance of preventing the appearance of these pharmacological interactions is because these 
are medicaments prescribed daily in odontology for moderate pain treatment and inflammation in the oral cavity. 
Paracetamol can interact with warfarin and therefore care should be taken with chronic alcoholic patients. All NSAIs 
reduce renal blood flow and consequently are capable of reducing the efficacy of medicaments used for treating 
arterial hypertension, which act via a renal mechanism. Especial attention should be taken considering the risk of 
interaction between the antagonists of AT1 receptors of angiostensin II (ARAII) and the NSAIs.
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Introduction
There are various adverse pharmacological interac-
tions implicating narcotic analgesics, paracetamol and 
NSAI that the oral cavity specialist should be aware of. 
The objective of this second article is to describe the 
pharmacological interactions which have major clinical 
repercussions in dental practice derived from prescribing 
these medicaments to prevent adverse reactions. Thus the 
need to carry out a detailed clinical history of the patients´ 
general health (systemic pathologies), and investigate 
medication being received which could interact with 
anti-inflammatory-analgesics.
Interaction of narcotic analgesics
Narcotics are depressors of the central nervous system 
(CNS) which combine with various subtypes of opiate 
receptors in the brain, spinal and peripheral medulla. 
Narcotic analgesics like codeine, dihydrocodeine, oxyco-
done, tramadol and propoxyphene can be prescribed 
by odontologists in combination with optimal doses of 
paracetamol or ibuprofen in order to produce less adverse 
effects than by administering a single raised dose of the 
narcotic (1). The opiate and central analgesics have addi-
tive sedatory and respiratory depressor effects together 
with other depressors of the CNS such as sedatory anti-
histamines, anti-depressors, anti-psychotics, ansiolytics, 
anticonvulsives, hypnotic sedatives and medicaments 
for cough (2). Of special interest in pediatric odontology 
is the potential additive effect of high doses of seda-
tory narcotics used with local anaesthetics in children 
because of the associated toxic anaesthetic reactions. 
The opiate component of the sedative can also induce 
respiratory acidosis which reduces the combination of 
local anaesthetics with proteins resulting in an excess of 
free anaesthetic that CNS cannot distribute. Besides the 
partial elevation of carbon dioxide pressures produced by 
opiate premedication increases sensitivity to convulsions 
induced by the local anaesthetic. (3, 4,) Herbal medicines 
like kava (for treatment of anxiety), and valerian (used 
as a sedative and tranquilizer) can also increase sedation 
by opiates.
The majority of opiate analgesics like codeine, tramadol, 
meperidine, and central analgesics are metabolized by 
CYP2D6 suggesting that codeine and tramadol are subs-
trates of CYP2D6 and are therefore promedicaments (5). 
Antiviral medicaments like ritonavir and cimetidine (H1 
antagonist) increase the opiate effect. It has been shown 
that the administration of antiarrhythmic quinidine eli-
minates the analgesic activity of codeine and tramadol 
(6). It is more important for the dentist to be aware of the 
interaction of the Selective Inhibition of Recaptation of 
Serotonin (SIRS) which has the theoretic potential of 
reducing the analgesic activity of codeine and trama-
dol (1, 5, 6,). Table 1 shows some medical inhibitors of 
CYP2D6 that can interact with opiate analgesics (7). The 
inducers of CYP2D6 reduce the efficacy of the opiates 
(they already accelerate its metabolism). Accordingly, in 
patients undergoing treatment with a CYP2D6 inducer, 
the opiate doses may have to be raised. The CYP2D6 
inducers include anticonvulsives, carbamazepine, 
phenobarbital phenitoin, primidona and rifampicin (for 
treatment of tuberculosis). 
Meperidine is a synthetic narcotic used orally for pedia-
tric sedation and occasionally as an analgesic in odon-
tology (8). When administering meperidine to patients 
receiving other serotoninergic medications including 
other antidepressors and medicaments for treatment of 
conduct disorders a serotoninic syndrome could result 
(9). The serotoninic syndrome is the result of excess 
production and maintenance of serotonin in the synaptic 
space. It is characterised by symptoms at the cognitive, 
autonomic and neuromuscular levels. The more preva-
lent symptoms can include confusion, disorientation 
and agitation, symptoms of autonomic nervous system 
of hypothermia, diaphoresis, sinus tachycardia, hy-
pertension, dilated pupils, tachypnea and nausea. The 
more profound interactions occur in patients taking 
SIRS (fluvoxamine, fluoxetine, paroxetine, sertraline, 
citalopram), depending on the doses. Other agents that 
block the recaptation of serotonin and norepinephrine 
can provoke, to a lesser extent, a syndrome of serotonin 
just like many antidepressors and herbal medicines such 
as the “San Juan” herb.
Grave and dangerous life threatening incidents have been 
reported in patients undergoing treatment with MAOI 
(phenylzine tranylcypromine, isocarboxazides and seli-
gilinine- anti-Parkinson-) and have also been prescribed 
therapeutic doses of meperidine (synthetic narcotic de-
rivative). Tramadol and propoxyphene, possibly via its 
own serotoninergic activity, have produced serotoninic 
syndromes when associated with MAOI. Finally, mepe-
ridine, tramadol and propoxyphene should be avoided in 
SIRS ANTIARRHYTHMICS ANTIDEPRESSORS ANTIPSYCHOTICS
Fluoxetina
Paroxetina
Sertralina
Quinidine
Amiodarone
Mibefradil
Propafenone
Clomipramine
Desipramine
Haloperidol
Tioridazine
Flufenazine
Table 1. Medicament inhibitors of CYP2D6 which can interact with opiate analgesics.
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patients who have been under treatment with MAOI for 
the past 14 days as hyperphenylalaninemia (an increase 
of phenylalanine in blood during fasting) can arise, and 
this is dangerous for the life of the patient (2).
Interactions with paracetamol
Paracetamol or acetaminophen is an analgesic used for 
treating mild to moderate pain and the advantage over 
NSAI is the absence of collateral effects. It is a potent 
analgesic similar   to acetylsalicylic acid but it is a gastric 
non-irritant. It is also safe when used in recommended 
doses over short periods of time which makes it recom-
mendable in odontological practice (1,3). Pharmacologi-
cal interactions have been reported between paracetamol 
and sulphinpirazones, phenitoin and zidovudine which 
are not clinically relevant in odontology if paracetamol 
is used in therapeutic doses during short periods of time. 
The interactions with paracetamol of interest to the odon-
tologist are with warfarin and with alcohol (3).
- Interaction of paracetamol with warfarin
Various interactions between paracetamol and warfarin 
have been published. Different studies indicate that pa-
racetamol produces a dose-dependent increase of INR in 
patients undergoing treatment with warfarin (7-11). This 
could result in hemorrhages in relation to the intensity 
of anticoagulation particularly when the INR is greater 
than 4.  Patients taking 9.100 mg of paracetamol a week 
have 10 times more risk of having an INR greater than 
6 (7). The mechanism by which this pharmacological 
interaction is produced is based on the saturation of P450 
cytochrome enzymes, which are responsible for meta-
bolizing warfarin because of the raised concentrations 
maintained during paracetamol activity. For this reason 
paracetamol only or in combination with opiates should 
be prescribed with precaution in patients receiving anti-
coagulants with warfarin. (7).
- Interaction of paracetamol with alcohol
Alcohol, considered a social drink, can have unnoticed 
pharmacological effects especially in the central nervous 
system. The ease of obtaining alcohol and paracetamol 
without prescription should make health specialists aware 
of possible interactions when prescribing paracetamol to 
chronic alcoholics. In clinical odontology it is difficult 
to identify chronic alcoholics. Generally, patients do 
not recognise their addiction and do not consider their 
consumption as excessive. Therefore the clinical history 
should be investigated thoroughly for suspected signs 
of excessive consumption However, the main reason for 
consultation is pain which obliges the odontologist to 
prescribe daily analgesics. As paracetamol lacks gastric 
effects it is widely prescribed.
In the metabolism of paracetamol the enzyme CYP2E1 
(belonging to the group of oxidative enzymes of cyto-
chrome P450) has an essential role. When this enzyme 
metabolises paracetamol it forms a highly hepatotoxic 
complex called NAPQI (n-acetyl-p-benzoquinonaimine) 
which is rapidly detoxified by hepatic glutation (Fig. 1). 
The CYP2E1 enzyme of the P450 cytochrome also in-
tervenes in the metabolism of ethanol. It has been shown 
that there is a risk of hepatic altercation when paracetamol 
is taken shortly before/after alcohol as alcohol induces 
CYP2E1 raising its concentration. Alcohol is the main 
substrate for the enzyme and inhibits other substrates like 
paracetamol. Consequently ethanol metabolism has an 
influencing role in inhibiting the non-toxic metabolism 
of paracetamol and the detoxification of NAPQI.
As a result of this conjugation it has been observed that 
a sole ingestion of 600 mg/kg of paracetamol in mice 
produces a notable hepatic lobular necrosis, hemorrhagic 
congestion and infiltration of erythrocytes but without 
damaging the hepatic parenchyma. The consumption of 
300 mg/kg paracetamol accompanied by ethanol produ-
ces lesions in the parenchyma and in the endothelium 
similar to a sole ingestion of 600 mg/kg paracetamol. 
As well as the altercations mentioned, the combination 
of these two substances, and always at the hepatic level, 
gives rise to stenosis and ischemic changes accompanied 
by a significant increase of hepatic proteins and transa-
minases (producing hepatic failure or death by hepatic 
coma) (12). Even so, the induction of the enzyme CYP2E1 
does not appear to adequately explain the magnitude of 
these adverse effects, assuming they influence other 
enzymes like CYP3A or mitochondrial glutation (MG). 
The toxicity of paracetamol shortly before/after alcohol 
consumption is the result of the induction of the enzyme 
CYP2E1. However, if consumption is spaced out over a 
period of time the toxicity is due to the induction of CY-
P2E1 and a selective depletion of mitochondrial MG.
At the immune system level, the combination of parace-
tamol and alcohol produces a progressive diminution of 
circulating leucocytes, and a relative weight reduction 
of the liver, spleen and thymus in comparison with the 
Fig. 1. Metabolism of paracetamol and alcohol.
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consumption of alcohol alone. There is also a significant 
reduction of platelet precursors, hemaglutination of sheep 
erythrocytes and IgG antibodies in response to bovine 
serum albumen. Accordingly, there is a tendency of pha-
gocyte suppression when both substances are combined. 
In animal experiments at the renal level, the association 
of both substances induces an increase in the effect on the 
proximal tubule cells because of paracetamol. However, 
the activity of urinary N-acetylglucoronidase, a lysoso-
mal enzyme preferentially located in renal proximal tu-
bules and which catalyses the hydrolysis of glucoronisides 
and glucoronates and alcohols, is significantly greater. 
Alcoholic mothers, who consume paracetamol, can via 
maternal milk, induce a renal effect in the suckling, 
including a reduction of weight. 
The more interesting interaction for the odontologist is 
that of paracetamol in chronic alcoholic patients (1, 13) 
as its major drawback is hepatic toxicity resulting from a 
toxic metabolite produced in the liver by the P-450 cyto-
chrome enzyme system, mainly cytochrome CYP2E1, 
which is normally detoxified by hepatic glutation (2). 
Ethanol is also detoxified by CYP2E1, which in turn is 
an inducer of ethanol, thus chronic ingestion raises the 
level of this enzyme (Fig. 1). When alcohol consumption 
is stopped, CYP2E1 is highly increased and exclusively 
metabolises paracetamol giving rise to large quantities 
of hepatotoxic metabolites which hepatic glutation is 
incapable of detoxifying thereby producing irreversible 
liver damage (14). In non-alcoholic patients the adminis-
tration of ethanol and paracetamol produces less NAPQI 
than paracetamol alone. In alcoholic patients and regular 
consumers, sudden abstinence creates a higher risk of 
increasing the toxicity of paracetamol (Fig. 1). Therefore 
it is important for the patient not to suspend alcohol con-
sumption on being prescribing paracetamol (14).
Interaction of NSAIs
NSAIs are medicaments regularly prescribed in dental 
practice to treat pain and inflammation. NSAIs function 
by inhibiting prostaglandin-synthetase or cyclooxigenase 
(COX). COX exists in two isoforms, COX 1 and COX 2. 
COX 1 (constitutional) has homeostatic functions which 
includes the maintenance of gastric mucosa (4, 10, 15,). 
COX 2 (inducible) is implicated in inflammation and 
fever (Fig. 2). NSAIs can be non-selective inhibitors of 
COX, that is, they inhibit COX 1 and COX 2 and semi-
selective inhibitors of COX 2 (two or three times more 
selective in blocking COX 2 than COX 1) and highly 
selective inhibitors of COX 2 (seven times more selective 
in blocking the activity of COX 2) (Fig. 2). Acetyl sali-
cylic acid is unique among non-selective NSAIs in that 
it irreversibly acetyls COX 1 in platelets, which justifies 
its prescription as a cardioprotector. Regarding selective 
NSAIs of COX 2, some have been withdrawn (like ro-
fecoxib) because of the risk of severe thromboembolic 
phenomenon. Celecoxib has better tolerance and is less 
ulcerogenic than conventional NSAIs (however, it has 
not been demonstrated that there is less risk of digestive 
hemorrhagia, perforation or pyloric obstruction which 
also probably require gastro-protection in  risk patients). 
It has an increased potential for cardiovascular mortality 
via a thrombocytic phenomenon (under study). Etoricoxib 
and parecoxib should not be dispensed as they also show 
a cardiovascular risk by analogy with other coxib (16). 
Following is a description of pharmacological interac-
tions between NSAIs and other pharmacological groups 
of interest to the odontologist.
- NSAI anti-aggregates and oral anticoagulants
The most serious adverse effect of NSAIs is gastrointes-
tinal hemorrhage. The predisposition of gastrointestinal 
bleeding of NSAI is based on damage produced in the 
gastric mucosa and in the inhibition of platelet aggrega-
tion via its effects on COX 1 (Fig. 2). NSAIs are contra-
indicated in patients taking other platelet anti-aggregates 
like dipiridamol, ticlopidine, anagrelide, clopidogrel or 
oral anticoagulants like warfarin or dicumarol, because of 
hemorrhagic risk (4). Besides, the hypoprothrombinemic 
effect is increased by NSAIs. Non selective NSAI should 
be used with precaution in patients under treatment with 
acetyl salicylic acid and other salicylates as they also 
inhibit platelet aggregation and reduce the formation of 
platelet obstruction (17). It has been observed that acetyl 
salicylic acid is responsible for producing this interaction 
when elevated doses are used (> 3 g/day) (1). The NSAI 
of choice in patients undergoing treatment with oral an-
ticoagulants is diclophenaco (3). Herbal medicines like 
dong quai (used in treating menopause symptoms) garlic, 
ginkgo biloba and ginseng have antiplatelet effects and 
can also give rise to NSAI platelet inhibition (7).
- NSAI-Metotrexate
Metotrexate is an anti-neoplasic medicament and immu-
nosuppressive antagonist of folic acid. It inhibits dihydro-
folate reductase impeding the reduction of dihydrofolic 
acid in its active form (tetrahydrofolic), essential for the 
biosynthesis of purines and pyrimidines which inhibits 
the synthesis of cellular DNA and RNA. Metotrexate is 
used for the treatment of rheumatoid arthritis, psoriasis 
and cancer. It has a low therapeutic index (1, 3). For 
treating cancer it is administered in high doses with a 
potential secondary effect of thrombocytopenia, neu-
tropenia, acute renal failure and mucositis. For treating 
rheumatoid arthritis and other pathologies which require 
immunosuppression, lower doses are used which produce 
less secondary effects. NSAIs reduce renal clearance of 
metotrexate (possibly due to a lowering of perfusion of 
prostaglandins dependent on renal perfusion), which can 
produce a toxicity phenomenon (the same as when using 
high doses in cancer treatment). NSAIs which have been 
implicated in interactions with metotrexate are ketopro-
fen, flurbiprofen, naproxen and ibuprofen (1, 2, 18,). The 
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Fig. 3. Mechanism of action of anti-hypersensitive medicaments IACE and ARA II.
Fig. 2. Mechanism of action of NSAI.
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severity of these interactions is greater and can lead to 
renal failure and pancytopenia. The odontologist should 
be aware that it is not recommended to prescribe NSAIs 
in these patients, especially in those patients receiving 
high doses of metotrexate for cancer treatment. Besides, 
great care should be taken with patients who have other 
arthritic pathologies and are undergoing treatment with 
NSAI as it can produce an additive effect with the pro-
bability of gastrointestinal and renal damage.
- NSAI-lithium
Lithium carbonate (antipsychotic) is the medicament of 
first choice in patients with bipolar depression and in the 
maintenance of affective recurrent disorders. Lithium 
presents a low therapeutic index which frequently produ-
ces interactions with other medicaments, including with 
diet, resulting in intoxication risk. The adverse effects 
of excessive concentrations of lithium include polyurea, 
polidipsia, nauseas, vomitos, diarrheas, tremors and 
sedation which can also lead to convulsions, coma and 
death. NSAIs increase lithium concentrations in serum 
predisposing to toxicity as already described. It appears 
that it produces inhibition of renal prostaglandins which 
leads to an increase of reabsorption of lithium (lithium 
is mainly excreted by the kidneys) (2). Indometacine is 
the NSAI that has a greater effect. Increase of levels of 
lithium with ketorolac has been observed while sulindac 
and acetyl salicylic acid does not appear to alter its con-
centration.  Therefore it is advisable to prescribe NSAI 
over short periods of time to patients taking lithium 
especially elderly patients (3, 10, 19,). For safety it is 
recommended to control the plasmic levels of lithium 
and to adjust the doses (1).
- NSAI-antihypertensives
There is sufficient evidence to show pharmacological 
interactions between NSAIs and four groups of anti-
hypersensitive medicaments (1-3, 7, 8, 10,) (Table 2):
1) Inhibitors of Angiotensin Converter Enzyme 
(IACE).
2) Antagonists of AT1 receptors of Angiotensin 
(ARAII).
3) Diuretics.
4) Beta-blockers.
These actions depend partly on the mechanisms of renal 
prostaglandins which have an anti-hypertensive effect 
(20). Evidence for the interaction of NSAI with these 
anti-hypertensives comes from numerous cases publis-
hed and from clinical trials (20). NSAI can increase the 
mean arterial pressure to 5 mmHg, above all naproxen 
and ibuprofen (6, 21). The effect of NSAI interaction 
with anti-hypertensives is observed from the fifth day 
of combined treatment.
1) IACE: The IACEs (captopril, analapril, fosino-
pril,lisinopril) (Table 2) produce vasodilatation by bloc-
king the formation of angiotensin 11 and aldosterone, 
with a parallel increase of bradiquine and vasodilator 
prostaglandins (Fig. 3). They act on the kidneys, in-
creasing renal plasma f low, reduce intraglomerular 
pression and maintain glomerular filtration.  Together 
with the tiazides they are the hypertensors that reduce 
the hypertrophy of the left ventricle the most. The IACE 
improve the prognosis of diabetes type 1 hypertensive 
patients, insufficient cardiac congestion (ICC) and pos-
IACE* ARA II** BETA-BLOCKERS ASA DIURETICS TIAZIDE DIURETICS
Benazepril
Captopril
Enalapril
Fosinopril
Lisinopril
Imidapril
Quinapril
Ramipril
Trandolapril
Candesartan
Eprosartan
Irbesartan
Losartan
Telmisartan
Valsartan
Olmesartan
Acebutolol
Atenolol
Betaxolol
Bisoprolol
Metoprolol
Carteolol
Nadolol
Penbutolol
Pindolol
Propranolol
Sotalol
Timolol
Furosemide
Bumetanide
Etacrinic acid
Torasemide
Piretanide
Hydrochlorotiazide
Indapamide
Metolazone
Xipamide
Chlortalidone
Table 2 Antihypertensive medicaments whose effects are reduced by NSAIs
* IACE: Inhibitor of Angiostensin Converter Enzyme.
** ARA II: Antagonists of Receptors of Angiotensin II.
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tinfarction patients. The prostaglandins are substances 
which modulate vasodilatation, glomerular filtration, 
renal tubular secretion of sodium and water and the 
rennin-angiotensin-aldosterone system. The NSAIs can 
attenuate the action of the IACE directly by inhibiting 
the synthesis of renal prostaglandin and indirectly by 
interfering with the production of prostaglandin induced 
by the IACEs (1-3, 7, 10).
2) ARA II: the antagonists of AT1 receptors of angio-
tensin II (ARAII) are a group of medicaments which 
antagonize the action of angiotensin II through media-
tion, independently of its route of synthesis (Table 2). In 
the presence of ARAII, angiotensin II stimulates AT2 
receptors, producing diverse activity contraarresting 
those mediated by AT1 receptors (Fig. 3) (22). In Spain, 
the following are commercialised: losartán candesertán, 
eprosartán, irbesartán, olmesartán, telmisartán, valsartán 
of which potassium losartán serves as a reference for 
this group (23). They produce vasodilatation, reduction 
of the liberation of catecholamines at the adrenal and 
presynaptic levels, of aldosterone and vasopressin, to-
gether with a lowering of peripheral resistance. It also 
produces a discreet increase of the elimination of Na, K, 
Cl, Mg and uric acid. The ARAII are effective and safe 
anti-hypertensive medicaments. Actually its basic use is 
in the treatment of arterial hypertension. Hypertensive 
patients with diabetes mellitus type 2 and incipient ne-
phropathy, both losartán and irbesartán reduce the risk of 
terminal renal illness. Its habitual role in therapy is as an 
alternative to IACE when these are not tolerated (patients 
with cardiac insufficiency are intolerant to IACE). On 
the other hand losartán has been shown to reduce the 
risk of AVC in hypertensive patients with left ventricular 
hypertrophy. Regarding the possible interactions of this 
group of hypertensive medicaments with NSAIs, there 
is evidence that the NSAIs can inhibit the vasodilatatory 
and natriuretic activity of ARAII (24), but this is not well 
studied as yet. Therefore it would be prudent to consider 
the risk produced by a reduction of the hypertensive effect 
when prescribing NSAI to patients undergoing treatment 
with ARAII. The hypertensive effect of ARAII is raised 
when associated with other anti-hypertensive agents 
and  also when combined with tiazides or renal U-tube 
diuretics to contra arrest the hypopotassemia that these 
diuretics produce (24).
3) Diuretics: diuretics are much prescribed. They reduce 
the renal reabsorption of sodium and chlorine. The diffe-
rent segments of neurons on which they act determine its 
potency and classification. Their more frequent uses are 
treatment of cardiac, hepatic or renal edema, essential 
arterial hypertension and hydroelectrolytic disturbances 
or acid-base equilibrium. The tiazide diuretics act by 
inhibiting the re-absorption of sodium in the distal tubule 
and connecter segment while the renal U-loop diuretics 
(their action is more potent and rapid than the tiazides) 
inhibit the transport of chlorine in the ascending renal 
U-loop of Henle (Table 2). The NSAIs interfere with the 
diuretics by reducing its efficacy in secreting sodium 
and affects the activity of plasma rennin (1-4, 7, 10, 
25,). This interaction is more evident in elderly patients 
having poor control of arterial hypertension, especially 
with ibuprofen. This interaction between indomethacin 
and furosemide has been reported.
4) Beta-blockers: the principal use of beta-blockers is 
treatment of arterial hypertension, ICC with ventricular 
systolic dysfunction, angina (stable and unstable), acute 
myocardial infarction, and arrhythmias. Beta-blockers 
reduce arterial pressure via diverse mechanisms, in-
cluding increase of levels of circulating of prostaglan-
din. It is well established that the beta-blocker-NSAI 
pharmadynamic interaction is particularly significant 
when the beta-blocker is administered for hypertension 
(1-4, 7, 10). Its effect can be inhibited by blocking the 
synthesis of prostaglandin induced by NSAIs (26). The 
anti-hypertensive medicaments which do not depend on 
renal prostaglandins are not implicated in the interaction 
with NSAIs. Thus the antagonists of calcium channels 
like nifedipin, verapamil, and diltiazem when adminis-
tered together with NSAI do not produce an increase in 
arterial pressure (2, 27). This data is important especially 
in patients requiring long term treatment with NSAIs (3, 
20). Regarding amlodipin, an increase in arterial pressure 
with ibuprofen has been observed. When prescribing 
NSAIs it is advisable, that with these antihypertensives 
(Table 2) the treatment does not exceed five days in 
order to avoid possible adverse reactions as a result of 
this pharmacological interaction (shown to be possibly 
life threatening). In any case, it is possible to produce 
an interaction, including during short term treatment 
in elderly patients, in patients with congestive cardiac 
insufficiency and cases of arterial hypertension with low 
rennin levels. Taking arterial pressure to control possible 
effects derived from this interaction makes it obligatory 
during treatment with NSAI.
- NSAI-ethanol
The combined use of alcohol and NSAI significantly 
increases the risk of bleeding (above all melenas) as-
sociated with ulcers and gastro-duodenal lesions. Both 
damage the gastric mucosa (especially acetyl salicylic 
acid) (1, 2, 10,). Ethanol stimulates gastric acids and leads 
to gastrointestinal bleeding induced by aceytl salicylic 
acid and prolongs the bleeding periods. Alcohol, on sti-
mulating the secretion of gastric acids, also aggravates 
the toxicity of NSAIs. It is suggested to space out intake 
of acetyl salicylic acid and alcohol by at least 12 hours. 
The severity of this interaction is normally probably only 
moderate (1, 2, 13,).
- NSAI-sirs
SIRS are anti-depressors of the “third generation”. To-
day, it is considered the first choice for the treatment of 
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depression and in a large variety of affective disorders 
because they are efficient and have few secondary effects. 
Over the past years an increase in postoperative bleeding 
after surgical intervention in the buccal cavity of patients 
taking these anti-depressors has been reported. Besides, 
a major risk of gastrointestinal hemorrhagia associated 
with SIRS has also been observed (7, 28). Just as the 
neurons in the CNS, the platelets have a mechanism for 
recaptation of serotonin and receptors. Platelets have no 
nucleus and are incapable of synthesising serotonin so 
the process of recaptation of serotonin from the blood 
stream is crucial for storing the platelets.  The liberation 
of this stored serotonin plays an important role in platelet 
aggregation. SIRS (as in the CNS) block the recaptation 
of serotonin inside the platelet producing a reduction in 
the regulation of serotonin on the surface of platelets 
(7, 28). This makes the SIRS like fluoxetin, paroxetin, 
sertralin, and citolapran produce a lowering of platelet 
function and an increased risk of bleeding (29). It has 
been shown that the combined administration of SIRS 
with NSAI (especially during prolonged intake) increases 
the risk of gastrointestinal bleeding (29). Some SIRS like 
fluvoxamine, paroxetine and sertraline are inhibitors of 
the CYP2C9 isoenzyme, while some NSAIs like diclofe-
naco, ibuprofen and naproxen are substrates for the same 
enzyme of P450 cytochrome (30). Therefore the combina-
tion of NSAI with ISRS can produce increased bleeding 
after oral surgical procedures. In fact until recently this 
was not taken into account when prescribing NSAIs in 
dental surgeries to patients undergoing treatment with 
SIRS (7, 10, 28-30).
- NSAI-oral hypoglucemics
Normally there is no adverse or clinically important 
interaction between hypoglycemic agents and NSAI. 
However, there are isolated cases of hypoglycaemia in 
patients taking fenclofenaco with chlorpropamide and 
metformine, glibenclamide with diflunisal, and ibuprofen 
with sulfonylurea. Other cases describe a loss of control 
of the diabetes attributed to indomethacin. It has been 
observed that piroxicam auments the effects of glibencla-
mide (2). It is clear that they can produce adverse interac-
tion in hypoglycemics and azapropazone, fenilbutazone, 
oxifenbutazone and the salicylates (2).
Conclusions
Opiate and central analgesics have additive sedatory 
and respiratory depressor effects with other depressors 
of CNS. They also react with SIRS and serotoninergic 
medication. The interactions, which, in odontological 
practice, have more repercussions, are between parace-
tamol and warfarin and alcohol. Prescription of NSAIs 
in arterial hypertensive patients treated with IACE, 
beta-blockers, diuretics (of renal U-tube and tiazides) 
and recently incorporated medicaments like ARAII can 
increase bleeding after buccal surgery. In fact, until re-
cently this was not taken into account when prescribing 
NSAI in odontology.
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